Morphic Therapeutic, a biotechnology company developing oral integrin therapies, has entered into a research and development collaboration with Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.
Merck has signed an agreement to acquire late-stage immunotherapy firm, Immune Design, in a deal valued at around $300m.
Peloton Therapeutics, a drug discovery and development company advancing oral medicines for cancer and other serious conditions, has announced the closing of an oversubscribed $150 million Series E financing.
Knight Therapeutics, a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription pharmaceutical products and Moksha8, a specialty pharmaceutical company focused on licensing and marketing innovative and established therapeutics in Latin America, announced the closing of a strategic financing agreement for up to $125m.
Decipher Biosciences (formerly GenomeDx) has announced a research collaboration with Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, to apply genomic tumor profiling using the Decipher assay and GRID software to identify prostate cancer patients on active surveillance who may benefit most from treatment with sipuleucel-T.
Researchers have created new machine learning software that can forecast the survival rates and response to treatments of patients with ovarian cancer.
Bayer has obtained the full rights to global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from the US-based Loxo Oncology.
SK Biopharmaceuticals has entered into a $530m deal with the Arvelle Therapeutics for investigational antiepileptic drug cenobamate.
Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, has announced a $42m Series A financing round led by 5AM Ventures and RA Capital Management.
AbbVie, Teneobio, and its affiliate TeneoOne have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.